Generic Semaglutide Online: What FDA's October 2026 Warning Letters and the Counterfeit Ozempic Case Mean for You

Within one week, FDA acted against counterfeit Ozempic and against websites selling semaglutide under made-up brand names. Here is what each document says, what it leaves out, and how to check a program and its pharmacy before you pay.

What did FDA's October 2026 warning letters say about "generic semaglutide" websites?

Both letters come from FDA's Office of Drug Security, Integrity, and Response, signed by its director, Sangeeta Vaswani Chatterjee, PharmD. FDA reviewed each site on August 26 and September 2, 2026.

Letter 737806 (onlinegenericmedicine.com). The product was "Semanat Injection (Semaglutide)." FDA found the company "failed to obtain approved applications pursuant to section 505," that the labeling "fails to bear adequate directions for use," and that the site was "offering the aforementioned drug product without requiring a prescription."

Letter 737810 (cheapmedicineshop.com). Addressed to a contact in India, it quotes the site: "Semanext Injection is a weekly injectable medicine used for controlling blood sugar in adults." FDA calls these "unapproved and misbranded injectable semaglutide drug products." This letter does not say the site sold without a prescription.

Both letters name Ozempic and Wegovy as the FDA-approved semaglutide injections, and both give the sites 15 business days to reply to FDA's Internet Pharmacy Task Force.

What is the counterfeit Ozempic case FDA announced?

FDA's September 29 release says the U.S. Attorney's Office for the Middle District of Florida and the Justice Department's Criminal Division charged Swapnadip Roy, 33, and Vicky Ramancha, 37, both Indian nationals, with conspiracy and smuggling. Court documents allege that from July 2023 to April 2024 they obtained counterfeit Ozempic from unauthorized sources in China, with fake packaging, inserts, pen labels and needles, sold it to U.S. distributors at steep discounts, and kept going after FDA's December 2023 seizure and public warning.

The release does not say the product was sold to patients through websites, and it states: "An indictment is merely an allegation." The fakes allegedly came with counterfeit packaging, inserts, pen labels and needles, so a brand name on the box proves little; the pharmacy's license matters.

Is generic semaglutide sold online legit?

Not in the form these letters describe. Both sellers put invented names on injectable semaglutide that FDA says was never approved.

This is a separate question from compounded semaglutide. A compounded drug made by a state-licensed 503A pharmacy on an individual prescription is also not FDA-approved. FDA's GLP-1 concerns page (current as of October 1, 2026) says "compounded drugs are not FDA approved." It is still a different legal category from a website shipping vials with no prescription; our 503A vs 503B pharmacy guide explains. FDA has also targeted compounders, including Empower Pharmacy in September (see our Empower pharmacy profile).

The same FDA page warns that "semaglutide sodium and semaglutide acetate, are different active ingredients than are used in the approved drugs."

How do you tell a licensed telehealth program from a flagged website?

The table matches FDA's published red flags against what each letter actually states. For program-level signals, see our telehealth red-flags checklist and how to tell if an online GLP-1 provider is legit.

How do you verify the pharmacy and prescriber yourself?

1. State board of pharmacy. FDA's "Locate a State-Licensed Online Pharmacy" page links to each state's license database. It says that if the pharmacy is not listed, "you should not use that pharmacy."
2. BeSafeRx. FDA's consumer page says a site "may be an unsafe website if it" offers "deep discounts or prices that seem too good to be true" or "does not require a doctor's prescription."
3. Prescriber NPI. The CMS NPPES NPI Registry is a free, public search. Search the clinician's name; on October 15 it returned credential, specialty and state license numbers.
4. NABP. The National Association of Boards of Pharmacy runs Safe.Pharmacy and the .pharmacy domain program. Its site blocked our automated read on October 15, so we have not re-read its current wording.

Ask any program which pharmacy fills your order, then run step 1 on that name. Our pharmacy transparency review explains why programs that name their pharmacy score higher.

What this means for you

Anchor "too good to be true" to the manufacturer's own self-pay prices.

Worked example 1: brand Wegovy, paid in cash for a year. These prices come from NovoCare's Wegovy savings page, read October 15, 2026.

• Wegovy pill 1.5 mg: $149 per month × 12 = $1,788.
• Wegovy pen at $349 per month × 12 = $4,188.
• Wegovy pen for a new patient: 2 introductory fills at $199 + 10 fills at $349 = $398 + $3,490 = $3,888.

The 1.5 mg pill costs $4,188 − $1,788 = $2,400 less per year than the full-price pen, though the two are different products and doses. Caveats: NovoCare says "Pricing to be updated after December 31, 2026," so a 12-month total starting now crosses that date, and higher pill doses cost more ($199 at 4 mg; $299 at 9 and 25 mg). See our semaglutide cost guide for every tier.

Worked example 2: FDA's 28-day vial rule. FDA's page says to "Discard the vial within 28 days after the first use, even if medication remains in the vial." On a once-weekly schedule, you first use the vial on day 0, then on days 7, 14 and 21. The next dose falls on day 28, the edge of the window. So plan on four doses per vial. If a hypothetical vial held enough for eight weekly doses, 8 − 4 = 4 doses (half the vial) would be thrown away. The rule applies to licensed compounded vials too.

If you have already bought from a site like these, stop using the product. Report it through FDA's "Report a problem to the FDA" page, as the September 29 release suggests, or call 888-INFO-FDA. Our Wegovy medication page covers the approved product.